Literature DB >> 19038779

Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation.

Sarah J Farnsworth1, Trent J Volz, Glen R Hanson, Annette E Fleckenstein.   

Abstract

Cocaine is a psychostimulant that inhibits the inward transport of dopamine (DA) via the neuronal DA transporter, thereby increasing DA concentrations in the synaptic cleft. Cocaine administration also causes a redistribution of striatal vesicular monoamine transporter (VMAT)-2-containing vesicles that co-fractionate with synaptosomal membranes after osmotic lysis (referred to herein as membrane-associated vesicles) to a nonmembrane-associated, cytoplasmic subcellular fraction. Although previous studies from our laboratory have focused on the impact of cocaine on cytoplasmic vesicles, the present report describes the pharmacological effects of cocaine on the membrane-associated vesicle population. Results revealed that the redistribution of VMAT-2 and associated vesicles away from synaptosomal membranes is associated with a decrease in total DA transport and DA content in the membrane-associated VMAT-2-containing subcellular fraction. Cocaine also decreases the velocity and magnitude of K+-stimulated exocytotic DA release from whole striatal suspensions. The cocaine-induced VMAT-2 redistribution, decrease in DA release, and decrease in total DA transport are mediated by D2 receptors as these events were prevented by pretreatment with the D2 receptor antagonist, eticlopride [S-(-)-3-chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxybenzamide hydrochloride]. These data suggest that after cocaine administration, D2 receptors are activated because of increased synaptic DA, resulting in a redistribution of DA-containing vesicles away from synaptosomal membranes, thus leading to less DA released after a depolarizing stimulus. These findings provide insight into not only the mechanism of action of cocaine but also mechanisms underlying the regulation of dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19038779      PMCID: PMC2682259          DOI: 10.1124/jpet.108.146159

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

Review 1.  Presynaptic control of quantal size: kinetic mechanisms and implications for synaptic transmission and plasticity.

Authors:  Guosong Liu
Journal:  Curr Opin Neurobiol       Date:  2003-06       Impact factor: 6.627

2.  Acute administration of cocaine regulates the phosphorylation of serine-19, -31 and -40 in tyrosine hydroxylase.

Authors:  Jakub P Jedynak; Syed F Ali; John W Haycock; Bruce T Hope
Journal:  J Neurochem       Date:  2002-07       Impact factor: 5.372

3.  Role of the D2 dopamine receptor in molecular adaptation to chronic hypoxia in PC12 cells.

Authors:  S Kobayashi; L Conforti; W H Zhu; D Beitner-Johnson; D E Millhorn
Journal:  Pflugers Arch       Date:  1999-11       Impact factor: 3.657

4.  Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

5.  Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.

Authors:  Jannine G Truong; Amy H Newman; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2004-11-03       Impact factor: 4.432

Review 6.  The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate.

Authors:  James O Schenk
Journal:  Prog Drug Res       Date:  2002

7.  Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.

Authors:  Verónica Sandoval; Evan L Riddle; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

8.  Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.

Authors:  Evan L Riddle; Matthew K Topham; John W Haycock; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2002-08-02       Impact factor: 4.432

9.  Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.

Authors:  Verónica Sandoval; Evan L Riddle; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

10.  Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2.

Authors:  Evan L Riddle; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2007-06-05       Impact factor: 4.432

View more
  11 in total

Review 1.  Vesicular and plasma membrane transporters for neurotransmitters.

Authors:  Randy D Blakely; Robert H Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

2.  Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Authors:  Pei-Wen Chu; Gregory C Hadlock; Paula Vieira-Brock; Kristen Stout; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2010-08-25       Impact factor: 5.372

3.  Modulating dopamine release by optogenetics in transgenic mice reveals terminal dopaminergic dynamics.

Authors:  Yao Lu; Nicolette Driscoll; Ilker Ozden; Zeyang Yu; Arto V Nurmikko
Journal:  Neurophotonics       Date:  2015-07-09       Impact factor: 3.593

4.  Cocaine self-administration produces pharmacodynamic tolerance: differential effects on the potency of dopamine transporter blockers, releasers, and methylphenidate.

Authors:  Mark J Ferris; Erin S Calipari; Yolanda Mateo; James R Melchior; David C S Roberts; Sara R Jones
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

5.  3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters.

Authors:  Charlotte P Magee; Christopher L German; Yasmeen H Siripathane; Peter S Curtis; David J Anderson; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2020-05-08       Impact factor: 4.030

Review 6.  Monoamine transporters: vulnerable and vital doorkeepers.

Authors:  Zhicheng Lin; Juan J Canales; Thröstur Björgvinsson; Morgane Thomsen; Hong Qu; Qing-Rong Liu; Gonzalo E Torres; S Barak Caine
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

7.  Chronic pre-exposure to methamphetamine following 31 days of withdrawal impairs sexual performance but not sexual conditioning in male Japanese quail.

Authors:  B Levi Bolin; Chana K Akins
Journal:  Behav Processes       Date:  2012-07-24       Impact factor: 1.777

8.  Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue.

Authors:  Trent J Volz; Sarah J Farnsworth; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurosci Methods       Date:  2009-03-28       Impact factor: 2.390

Review 9.  Advances in studying phasic dopamine signaling in brain reward mechanisms.

Authors:  Robert J Wickham; Wojciech Solecki; Liza R Rathbun; Nichole M Neugebauer; Robert Mark Wightman; Nii A Addy
Journal:  Front Biosci (Elite Ed)       Date:  2013-06-01

10.  Lipid peroxidation and apoptotic response in rat brain areas induced by long-term administration of nandrolone: the mutual crosstalk between ROS and NF-kB.

Authors:  Emanuela Turillazzi; Margherita Neri; Daniela Cerretani; Santina Cantatore; Paola Frati; Laura Moltoni; Francesco Paolo Busardò; Cristoforo Pomara; Irene Riezzo; Vittorio Fineschi
Journal:  J Cell Mol Med       Date:  2016-02-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.